193 related articles for article (PubMed ID: 35682660)
1. Gamma Secretase Inhibitors as Potential Therapeutic Targets for Notch Signaling in Uterine Leiomyosarcoma.
Abedin Y; Gabrilovich S; Alpert E; Rego E; Begum S; Zhao Q; Heller D; Einstein MH; Douglas NC
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682660
[TBL] [Abstract][Full Text] [Related]
2. Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways.
Cuppens T; Moisse M; Depreeuw J; Annibali D; Colas E; Gil-Moreno A; Huvila J; Carpén O; Zikán M; Matias-Guiu X; Moerman P; Croce S; Lambrechts D; Amant F
Int J Cancer; 2018 Mar; 142(6):1230-1243. PubMed ID: 29063609
[TBL] [Abstract][Full Text] [Related]
3. Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma.
Yang Q; Falahati A; Khosh A; Mohammed H; Kang W; Corachán A; Bariani MV; Boyer TG; Al-Hendy A
Cells; 2022 Nov; 11(23):. PubMed ID: 36497061
[TBL] [Abstract][Full Text] [Related]
4. Roles of Matrix Metalloproteinases 2 and 9 in Uterine Leiomyosarcoma.
Wang X; Li C; Lou L; Zhu H
Anticancer Res; 2024 Apr; 44(4):1465-1473. PubMed ID: 38537953
[TBL] [Abstract][Full Text] [Related]
5. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.
Shan W; Akinfenwa PY; Savannah KB; Kolomeyevskaya N; Laucirica R; Thomas DG; Odunsi K; Creighton CJ; Lev DC; Anderson ML
Clin Cancer Res; 2012 Jun; 18(12):3352-65. PubMed ID: 22535157
[TBL] [Abstract][Full Text] [Related]
6. The Functional Role and Regulatory Mechanism of FTO m
Yang Q; Al-Hendy A
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175660
[TBL] [Abstract][Full Text] [Related]
7. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas.
Anderson SE; Nonaka D; Chuai S; Olshen AB; Chi D; Sabbatini P; Soslow RA
Int J Gynecol Cancer; 2006; 16(2):849-53. PubMed ID: 16681772
[TBL] [Abstract][Full Text] [Related]
8. The Functional Role and Regulatory Mechanism of Bromodomain-Containing Protein 9 in Human Uterine Leiomyosarcoma.
Yang Q; Bariani MV; Falahati A; Khosh A; Lastra RR; Siblini H; Boyer TG; Al-Hendy A
Cells; 2022 Jul; 11(14):. PubMed ID: 35883603
[TBL] [Abstract][Full Text] [Related]
9. Functionality of the Tumor Suppressor
Stope MB; Cernat V; Kaul A; Diesing K; Koensgen D; Burchardt M; Mustea A
Anticancer Res; 2018 Mar; 38(3):1547-1550. PubMed ID: 29491084
[TBL] [Abstract][Full Text] [Related]
10. MMP14 expression and collagen remodelling support uterine leiomyosarcoma aggressiveness.
Gonzalez-Molina J; Hahn P; Falcão RM; Gultekin O; Kokaraki G; Zanfagnin V; Braz Petta T; Lehti K; Carlson JW
Mol Oncol; 2024 Apr; 18(4):850-865. PubMed ID: 37078535
[TBL] [Abstract][Full Text] [Related]
11. Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma.
Kodama M; Shimura H; Tien JC; Newberg JY; Kodama T; Wei Z; Rangel R; Yoshihara K; Kuruma A; Nakae A; Hashimoto K; Sawada K; Kimura T; Jenkins NA; Copeland NG
Cancer Res; 2021 Nov; 81(21):5413-5424. PubMed ID: 34475109
[TBL] [Abstract][Full Text] [Related]
12. Copper ions are novel therapeutic agents for uterine leiomyosarcoma.
Kakuda M; Matsuzaki S; Ueda Y; Shiomi M; Matsuzaki S; Kimura T; Fujita M; Egawa-Takata T; Kobayashi E; Serada S; Yoshino K; Naka T; Kimura T
Am J Obstet Gynecol; 2020 Jan; 222(1):64.e1-64.e16. PubMed ID: 31351063
[TBL] [Abstract][Full Text] [Related]
13. Uterine Leiomyosarcoma Tumorigenesis in Lmp2-deficient Mice: Involvement of Impaired Anti-oncogenic Factor IRF1.
Hayashi T; Horiuchi A; Sano K; Yaegashi N; Konishi I
Anticancer Res; 2015 Sep; 35(9):4665-79. PubMed ID: 26254356
[TBL] [Abstract][Full Text] [Related]
14. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
Harold J; Bellone S; Manavella DD; Mutlu L; McNamara B; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MS; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2023 Jan; 168():157-165. PubMed ID: 36442427
[TBL] [Abstract][Full Text] [Related]
15. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
[TBL] [Abstract][Full Text] [Related]
16. Curcumin induces cross-regulation between autophagy and apoptosis in uterine leiomyosarcoma cells.
Li B; Takeda T; Tsuiji K; Wong TF; Tadakawa M; Kondo A; Nagase S; Yaegashi N
Int J Gynecol Cancer; 2013 Jun; 23(5):803-8. PubMed ID: 23532091
[TBL] [Abstract][Full Text] [Related]
17. Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications.
Dhingra S; Rodriguez ME; Shen Q; Duan X; Stanton ML; Chen L; Zhang R; Brown RE
Int J Clin Exp Pathol; 2010 Jan; 4(2):134-46. PubMed ID: 21326806
[TBL] [Abstract][Full Text] [Related]
18. Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment.
An Y; Wang S; Li S; Zhang L; Wang D; Wang H; Zhu S; Zhu W; Li Y; Chen W; Ji S; Guo X
BMC Cancer; 2017 Sep; 17(1):639. PubMed ID: 28893210
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic value of Bcl-2 in uterine leiomyosarcoma.
Travaglino A; Raffone A; Raimondo D; Gencarelli A; Esposito I; Gallo C; Improda FP; Vitale SG; Mollo A; Casadio P; Seracchioli R; Zullo F; Insabato L
Arch Gynecol Obstet; 2023 Feb; 307(2):379-386. PubMed ID: 35344084
[TBL] [Abstract][Full Text] [Related]
20. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
McNamara B; Harold J; Manavella D; Bellone S; Mutlu L; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Yang K; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Burton EA; Inagaki H; Albers A; Zhang C; Bollag G; Schlessinger J; Santin AD
Gynecol Oncol; 2023 May; 172():65-71. PubMed ID: 36958197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]